Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Alzheimer Disease D000544 76 associated lipids
Anorexia D000855 8 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Ataxia D001259 20 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Body Weight D001835 333 associated lipids
Bradycardia D001919 13 associated lipids
Brain Concussion D001924 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Brain Edema D001929 20 associated lipids
Breast Neoplasms D001943 24 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bulimia D002032 3 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Catalepsy D002375 30 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Cough D003371 19 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Edema D004487 152 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Fatty Liver D005234 48 associated lipids
Fever D005334 35 associated lipids
Fibromyalgia D005356 4 associated lipids
Glioma D005910 112 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperemia D006940 25 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperkinesis D006948 11 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Learning Disorders D007859 11 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Migraine Disorders D008881 11 associated lipids
Morphine Dependence D009021 9 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Muscle Spasticity D009128 5 associated lipids
Mycoses D009181 18 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms D009369 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuralgia D009437 28 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Pain D010146 64 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Seizures D012640 87 associated lipids
Shock, Septic D012772 11 associated lipids
Sleep Deprivation D012892 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Urinary Incontinence D014549 4 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Ocular Hypotension D015814 2 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Endotoxemia D019446 27 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Czifra G et al. Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells. 2012 J. Invest. Dermatol. pmid:22513781
Turcotte C et al. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. 2015 J. Leukoc. Biol. pmid:25877930
Oka S et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. 2004 J. Leukoc. Biol. pmid:15316028
Jackson AR et al. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. 2014 J. Leukoc. Biol. pmid:24319288
Glass M et al. Misidentification of prostamides as prostaglandins. 2005 J. Lipid Res. pmid:15863842
Newberry EP et al. Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice. 2012 J. Lipid Res. pmid:22327204
Ambrosi S et al. On the importance of anandamide structural features for its interactions with DPPC bilayers: effects on PLA2 activity. 2005 J. Lipid Res. pmid:15961786
Bojesen IN and Hansen HS Membrane transport of anandamide through resealed human red blood cell membranes. 2005 J. Lipid Res. pmid:15930521
Weber A et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. 2004 J. Lipid Res. pmid:14729864
Kantae V et al. Quantitative profiling of endocannabinoids and related -acylethanolamines in human CSF using nano LC-MS/MS. 2017 J. Lipid Res. pmid:27999147
Long JZ et al. An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. 2011 J. Lipid Res. pmid:21097653
Oddi S et al. Pitfalls and solutions in assaying anandamide transport in cells. 2010 J. Lipid Res. pmid:20447929
Fezza F et al. Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation. 2008 J. Lipid Res. pmid:18316795
Bojesen IN and Hansen HS Binding of anandamide to bovine serum albumin. 2003 J. Lipid Res. pmid:12837852
Jacome-Sosa M et al. Vaccenic acid suppresses intestinal inflammation by increasing anandamide and related N-acylethanolamines in the JCR:LA-cp rat. 2016 J. Lipid Res. pmid:26891736
Yang W et al. Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2. 2005 J. Lipid Res. pmid:16150817
Patel S et al. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. 2005 J. Lipid Res. pmid:15576840
Bojesen IN and Hansen HS Effect of an unstirred layer on the membrane permeability of anandamide. 2006 J. Lipid Res. pmid:16365480
Wollank Y et al. Inhibition of FAAH confers increased stem cell migration via PPARα. 2015 J. Lipid Res. pmid:26263913
Clugston RD et al. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. 2011 J. Lipid Res. pmid:21856784
Markey SP et al. Base- and acid-catalyzed interconversions of O-acyl- and N-acyl-ethanolamines: a cautionary note for lipid analyses. 2000 J. Lipid Res. pmid:10744787
Hillard CJ and Campbell WB Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. 1997 J. Lipid Res. pmid:9458263
Astarita G et al. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. 2008 J. Lipid Res. pmid:17957091
De Petrocellis L et al. Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. 2009 J. Lipid Res. pmid:19017617
McAllister SD et al. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. 2003 J. Med. Chem. pmid:14613317
Lambert DM and Fowler CJ The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. 2005 J. Med. Chem. pmid:16078824
Vandevoorde S et al. Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase. 2003 J. Med. Chem. pmid:14521402
Ng EW et al. Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. 1999 J. Med. Chem. pmid:10354405
Schiano Moriello A et al. Development of the first potential covalent inhibitors of anandamide cellular uptake. 2006 J. Med. Chem. pmid:16570928
Appendino G et al. Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. 2006 J. Med. Chem. pmid:16570929
Tarzia G et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. 2003 J. Med. Chem. pmid:12773040
López-Rodríguez ML et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. 2003 J. Med. Chem. pmid:12672252
Tuccinardi T et al. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. 2006 J. Med. Chem. pmid:16451064
Balas L et al. Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity. 2009 J. Med. Chem. pmid:19161308
Hanus L et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. 1993 J. Med. Chem. pmid:8411021
Cisneros JA et al. Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. 2007 J. Med. Chem. pmid:17764163
Barnett-Norris J et al. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. 1998 J. Med. Chem. pmid:9822555
Martín-Couce L et al. Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors. 2011 J. Med. Chem. pmid:21675776
Romero FA et al. Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. 2007 J. Med. Chem. pmid:17279740
Salo OM et al. 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data. 2006 J. Med. Chem. pmid:16420041
Avraham Y et al. Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY). 2013 J. Med. Chem. pmid:23384387
Onnis V et al. Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. 2010 J. Med. Chem. pmid:20143779
Li C et al. High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. 2005 J. Med. Chem. pmid:16190768
van der Stelt M et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. 2002 J. Med. Chem. pmid:12166944
López-Rodríguez ML et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. 2001 J. Med. Chem. pmid:11741470
Seltzman HH et al. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. 1997 J. Med. Chem. pmid:9357529
Lin S et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. 1998 J. Med. Chem. pmid:9876105
Fichera M et al. A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. 2000 J. Med. Chem. pmid:10882356
Brizzi A et al. Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor. 2011 J. Med. Chem. pmid:22044209
Ortar G et al. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. 2007 J. Med. Chem. pmid:18027904
Ryan WJ et al. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. 1997 J. Med. Chem. pmid:9357528
Appendino G et al. Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. 2009 J. Med. Chem. pmid:19361197
Thomas BF et al. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. 1996 J. Med. Chem. pmid:8558515
Brizzi A et al. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. 2009 J. Med. Chem. pmid:19331413
Sheskin T et al. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. 1997 J. Med. Chem. pmid:9057852
Feledziak M et al. SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process. 2011 J. Med. Chem. pmid:21899370
Lang W et al. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. 1999 J. Med. Chem. pmid:10072686
Brizzi A et al. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. 2005 J. Med. Chem. pmid:16279794
Khanolkar AD et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. 1996 J. Med. Chem. pmid:8893848
Palermo G et al. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. 2011 J. Med. Chem. pmid:21830831
Barnett-Norris J et al. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. 2002 J. Med. Chem. pmid:12166938
Wyffels L et al. Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo imaging of fatty acid amide hydrolase in the brain. 2009 J. Med. Chem. pmid:19719235
Tong W et al. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. 1998 J. Med. Chem. pmid:9784095
Vandevoorde S et al. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. 2003 J. Med. Chem. pmid:12672243
Lynch DL and Reggio PH Molecular dynamics simulations of the endocannabinoid N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics. 2005 J. Med. Chem. pmid:16033262
Ueda N et al. A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. 1998 J. Med. Invest. pmid:9864962
Amorós I et al. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. 2010 J. Mol. Cell. Cardiol. pmid:19616555
Weis F et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. 2010 J. Mol. Cell. Cardiol. pmid:19931541
Hoyer FF et al. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. 2014 J. Mol. Cell. Cardiol. pmid:24286707
Currie S et al. IP(3)R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. 2008 J. Mol. Cell. Cardiol. pmid:18692061
D'Argenio G et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. 2007 J. Mol. Med. pmid:17396241
Iuvone T et al. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. 2007 J. Mol. Med. pmid:17639288
Catani MV et al. Expression of the endocannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol. 2009 J. Mol. Med. pmid:18820887
Wang ZY et al. Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase. 2015 J. Mol. Neurosci. pmid:25374388
Lagalwar S et al. Anandamides inhibit binding to the muscarinic acetylcholine receptor. 1999 Aug-Oct J. Mol. Neurosci. pmid:10691292
Naidoo V et al. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. 2011 J. Mol. Neurosci. pmid:21069475
Hillard CJ et al. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. 2007 J. Mol. Neurosci. pmid:17901541
Han B et al. Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. 2003 J. Nat. Prod. pmid:14575438
Raduner S et al. Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. 2007 J. Nat. Prod. pmid:17497806
Hillard CJ et al. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. 1995 J. Neurochem. pmid:7830060
Lam PM et al. Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca(2+)](i), initiates neurotransmitter release and promotes delayed cell death. 2007 J. Neurochem. pmid:17442052
Subbanna S et al. Postnatal ethanol exposure alters levels of 2-arachidonylglycerol-metabolizing enzymes and pharmacological inhibition of monoacylglycerol lipase does not cause neurodegeneration in neonatal mice. 2015 J. Neurochem. pmid:25857698
Pearlman RJ et al. Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a. 2003 J. Neurochem. pmid:12558979
Maccarrone M et al. Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. 2004 J. Neurochem. pmid:15147522
Maccarrone M et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. 2003 J. Neurochem. pmid:12716433
Ahluwalia J et al. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. 2003 J. Neurochem. pmid:12558978
De Lago E et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. 2006 J. Neurochem. pmid:16899063
Sarmad S et al. Depolarizing and calcium-mobilizing stimuli fail to enhance synthesis and release of endocannabinoids from rat brain cerebral cortex slices. 2011 J. Neurochem. pmid:21375532
Hansen HH et al. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. 2001 J. Neurochem. pmid:11145976
Nogueron MI et al. Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. 2001 J. Neurochem. pmid:11677265
Vogel Z et al. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. 1993 J. Neurochem. pmid:8515284
Jarrahian A et al. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. 2000 J. Neurochem. pmid:10820223
Di Marzo V et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. 2000 J. Neurochem. pmid:10737621
Di Marzo V et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. 2000 J. Neurochem. pmid:11080195
Rubino T et al. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. 2000 J. Neurochem. pmid:11080200
Wiles AL et al. N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. 2006 J. Neurochem. pmid:16899062
Cadogan AK et al. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. 1997 J. Neurochem. pmid:9282935
Hill MN et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. 2008 J. Neurochem. pmid:18643796
Placzek EA et al. Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. 2008 J. Neurochem. pmid:18778304
Martin GG et al. FABP-1 gene ablation impacts brain endocannabinoid system in male mice. 2016 J. Neurochem. pmid:27167970